Investigation on Suicide Risk Factors of Patients With Mood Disorders
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age16-60
SponsorTianjin Anding Hospital
About this trial
This study investigates the level and distribution of suicide risk and learned suicide ability of patients with mood disorders, investigates the related risk factors of suicide and suicide ability formation of patients with mood disorders from multiple dimensions (biological, psychological, social and clinical perspectives) and clarifies their importance, forms a list of suicide risk factors, and establishes a prediction model of learned suicide ability formation. Upon enrollment, participants will undergo comprehensive assessments including blood and urine sample collection and scale evaluation. The collection of scientific blood and urine is mainly used for the exploration of molecular mechanism of disease occurrence and development, the discovery and verification of biomarkers. Scale evaluation includes: Beck Scale for Suicide Ideation , Columbia Suicide Severity Rating Scale,, Hamilton Depression Rating Scale , Hamilton Anxiety Rating Scale, PHQ-9, GAD-7, Personal and Social Function Scale , Schihan Disability Scale , Emotional Adjustment Difficulty Scale , Acquired Capability for Suicide Scale, Interpersonal Needs Questionnaire , Ottawa Self-Injury Scale, Chinese version of Stress Perception Scale and Beck Hopelessness Scale . Follow-up was carried out for 3 months, including whether suicide/self-injury occurred, current status, and some baseline questionnaires (such as BSI-CV, GAD-7, PHQ-9, HAMD-17,HAMA, etc.).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age: 16 to 60 years old;
seeing a doctor in a psychiatric clinic or a general hospital;
Willing to cooperate in this research project;
Sign the informed consent form (minors also need to obtain the informed consent signature of the guardian);
Disqualifiers
unable to understand the contents of the questionnaire;
Serious organic diseases such as cardiovascular disease, brain disease, liver disease and kidney disease, and weak body, which affect the respondents of the questionnaire;
Other circumstances that make it impossible or unwilling to cooperate with the completion of the questionnaire.
Trial population
This study will recruit 300 patients meeting the diagnostic criteria of ICD-11 mood disorder.The 300 subjects, aged16 to 60 years old, come from Tianjin Anding Hospital's inpatient/outpatient services and must consent to participate. Exclusion Criteria are as follows:(1) unable to understand the contents of the questionnaire;(2) Serious organic diseases such as cardiovascular disease, brain disease, liver disease and kidney disease, and weak body, which affect the respondents of the questionnaire;(3) Other circumstances that make it impossible or unwilling to cooperate with the completion of the questionnaire.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
300 Participants
are grouped into 1 trial groupGroup A: patients with mood disorders
Trial outcomes
Primary outcomes
1
Columbia Suicide Severity Rating Scale
Columbia Suicide Severity Rating Scale (C-SSRS) is a tool for evaluating the risk of individual suicide. It includes a series of questions to evaluate the frequency, intensity, persistence and concreteness of individual suicide behavior in the past period of time. The purpose of C-SSRS scale is to distinguish between suicidal ideation and suicidal attempt and higher scores mean a worse outcome. Developed by researchers from Columbia University, the scale is widely used in clinical and research fields to help identify and manage suicide risks.
Time frame
baseline, 3 monthsSecondary outcomes
1
Beck Scale for Suicide Ideation
Beck Scale for Suicide Ideation (BSI-CV) assesses the individual's thoughts about life and death and the severity of suicidal thoughts through series of questions. There are 19 items in the scale, which are divided into two dimensions: suicidal ideation and suicidal tendency. Each question is asked for two time periods, that is, the last week and the most depressed, melancholy or suicidal time in the past (that is, the most serious time). The scale adopts a three-level scoring system, that is, 0\~2 points, and the total score is between 0\~38 points. The higher the score, the stronger the suicidal ideation and the higher the risk of suicide.
Time frame
baseline, 3 months2
Hamilton Depression Rating Scale
Hamilton Depression Rating Scale (HAMD-17), also known as Hamilton Depression Rating Scale, is a clinical tool for evaluating the severity of depressive symptoms, mainly evaluating patients' depressive symptoms in the past week, including mood, sleep, cognitive function, behavior and physical symptoms. According to the specific performance of patients, doctors or clinical evaluators will give corresponding scores. The total score ranges from 0 to 52 points. The higher the total score, the more serious the depressive symptoms are.
Time frame
baseline, 3 months3
Hamilton Anxiety Rating Scale
Hamilton Anxiety Rating Scale (HAMA) is a clinical tool for evaluating the severity of anxiety symptoms. The scale was compiled by psychologist Hamilton in 1959, and it is widely used in clinical diagnosis, treatment effect evaluation and research work in psychiatry. HAMA contains 14 items, covering psychological anxiety and physical anxiety. Each item is scored according to the severity of symptoms, and the higher the total score, the more serious the anxiety symptoms are. The total score ranges from 0 to 56 points. Scoring standards are usually divided into four grades: mild, moderate, severe and extremely severe.
Time frame
baseline, 3 months4
Patient Health Questionnare
Patient Health Question Nare (PHQ-9): It contains 9 questions, mainly focusing on depressed mood, lack of pleasure, sleep disorder, decreased energy, change of appetite, difficulty in concentration, reduced sense of self-worth, negative ideas or suicidal thoughts. Scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.
Time frame
baseline, 3 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov